Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

18.87 -0.46 (-2.38%)

Streaming Delayed Price Updated: 2:34 PM EDT, Mar 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	709,202
Open	18.96
Bid (Size)	18.84 (200)
Ask (Size)	18.90 (100)
Prev. Close	19.33
Today's Range	18.59 - 19.50
52wk Range	9.235 - 19.95
Shares Outstanding	34,233,643
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

Today 7:00 EDT

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

March 25, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+22.1%	+22.1%
1 Month	+15.9%	+15.9%
3 Month	+24.4%	+24.4%
6 Month	+54.5%	+54.5%
1 Year	+63.5%	+63.5%

More News

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference

March 20, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

March 18, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

March 02, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

February 25, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline

February 18, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 12, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗

January 08, 2026

Via Stocktwits

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

January 08, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

December 22, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

These stocks are moving in today's session ↗

December 03, 2025

Via Chartmill

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

November 10, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Examining the Future: KalVista Pharma's Earnings Outlook ↗

November 10, 2025

Via Benzinga

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

November 06, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 05, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

November 03, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

October 30, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Via MarketMinute

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?

KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market

What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?

The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 18.87

When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 03/30/26 02:34 PM ET

What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?

The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 645.99M

How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?

KalVista Pharmaceuticals, Inc. - Common Stock has 646M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.